Black Diamond Therapeutics Appoints Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer
Retrieved on:
Wednesday, June 1, 2022
Diamond, Leadership, Achievement, Large-cell lung carcinoma, Company, Rucaparib, Program, Board of directors, EGFR, Glioblastoma, M26 Modular Accessory Shotgun System, First Pavlov State Medical University of St. Petersburg, Immunity (medical), Roche, Gaps, Cancer, ImClone Systems, Senior, GBM, Investigational New Drug, Research institute, Nasdaq, Ovarian cancer, Growth, Eli Lilly and Company, Â, Patient, GLOBE, Private Securities Litigation Reform Act, MAP, NEW, Clovis Oncology, Board, Drug discovery, Merck, NSCLC, Homologous recombination, U.S. Securities and Exchange Commission, Hematology, Black Diamond, Pharmaceutical industry, Risk management, IND
CAMBRIDGE, Mass. and NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer. In conjunction with the appointment of Dr. Yurasov, Karsten Witt, M.D., is transitioning from his current role as the Company’s Interim Chief Medical Officer to a clinical advisory role.
Key Points:
- and NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer.
- We are delighted to welcome Sergey to Black Diamond as Chief Medical Officer.
- Dr. Yurasov joins Black Diamond Therapeutics from Nuvation Bio, an oncology therapeutics company.
- Dr. Yurasov succeeds Dr. Witt, who was Black Diamonds founding Chief Medical Officer and will continue to support the Company in an advisory capacity.